203 related articles for article (PubMed ID: 10860939)
1. Cellular response to a glutathione S-transferase P1-1 activated prodrug.
Rosario LA; O'Brien ML; Henderson CJ; Wolf CR; Tew KD
Mol Pharmacol; 2000 Jul; 58(1):167-74. PubMed ID: 10860939
[TBL] [Abstract][Full Text] [Related]
2. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase.
Morgan AS; Sanderson PE; Borch RF; Tew KD; Niitsu Y; Takayama T; Von Hoff DD; Izbicka E; Mangold G; Paul C; Broberg U; Mannervik B; Henner WD; Kauvar LM
Cancer Res; 1998 Jun; 58(12):2568-75. PubMed ID: 9635580
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells.
Townsend DM; Shen H; Staros AL; Gaté L; Tew KD
Mol Cancer Ther; 2002 Oct; 1(12):1089-95. PubMed ID: 12481432
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways.
Ruscoe JE; Rosario LA; Wang T; Gaté L; Arifoglu P; Wolf CR; Henderson CJ; Ronai Z; Tew KD
J Pharmacol Exp Ther; 2001 Jul; 298(1):339-45. PubMed ID: 11408560
[TBL] [Abstract][Full Text] [Related]
5. Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester.
Nakajima T; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Abe T; Kato J; Sakon K; Naniwa Y; Tanabe H; Niitsu Y
J Pharmacol Exp Ther; 2003 Sep; 306(3):861-9. PubMed ID: 12805482
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferase.
Satyam A; Hocker MD; Kane-Maguire KA; Morgan AS; Villar HO; Lyttle MH
J Med Chem; 1996 Apr; 39(8):1736-47. PubMed ID: 8648613
[TBL] [Abstract][Full Text] [Related]
7. Glutathione peptidomimetic drug modulator of multidrug resistance-associated protein.
O'Brien ML; Vulevic B; Freer S; Boyd J; Shen H; Tew KD
J Pharmacol Exp Ther; 1999 Dec; 291(3):1348-55. PubMed ID: 10565860
[TBL] [Abstract][Full Text] [Related]
8. Activity of TER286 against human tumor colony-forming units.
Izbicka E; Lawrence R; Cerna C; Von Hoff DD; Sanderson PE
Anticancer Drugs; 1997 Apr; 8(4):345-8. PubMed ID: 9180387
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug.
Findlay VJ; Townsend DM; Saavedra JE; Buzard GS; Citro ML; Keefer LK; Ji X; Tew KD
Mol Pharmacol; 2004 May; 65(5):1070-9. PubMed ID: 15102935
[TBL] [Abstract][Full Text] [Related]
10. Glutathione-S-transferase activates novel alkylating agents.
Lyttle MH; Satyam A; Hocker MD; Bauer KE; Caldwell CG; Hui HC; Morgan AS; Mergia A; Kauvar LM
J Med Chem; 1994 May; 37(10):1501-7. PubMed ID: 8182709
[TBL] [Abstract][Full Text] [Related]
11. Detoxification of 1-chloro-2,4-dinitrobenzene in MCF7 breast cancer cells expressing glutathione S-transferase P1-1 and/or multidrug resistance protein 1.
Diah SK; Smitherman PK; Townsend AJ; Morrow CS
Toxicol Appl Pharmacol; 1999 Jun; 157(2):85-93. PubMed ID: 10366541
[TBL] [Abstract][Full Text] [Related]
12. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M
Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092
[TBL] [Abstract][Full Text] [Related]
13. The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance.
O'Brien M; Kruh GD; Tew KD
J Pharmacol Exp Ther; 2000 Aug; 294(2):480-7. PubMed ID: 10900222
[TBL] [Abstract][Full Text] [Related]
14. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance.
Harbottle A; Daly AK; Atherton K; Campbell FC
Int J Cancer; 2001 Jun; 92(6):777-83. PubMed ID: 11351295
[TBL] [Abstract][Full Text] [Related]
15. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
[TBL] [Abstract][Full Text] [Related]
16. Alterations in glutathione and glutathione-related enzymes in a multidrug-resistant small cell lung cancer cell line.
Cole SP; Downes HF; Mirski SE; Clements DJ
Mol Pharmacol; 1990 Feb; 37(2):192-7. PubMed ID: 1968221
[TBL] [Abstract][Full Text] [Related]
17. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of MCF-7(piGST) breast tumors using glutathione transferase-derived 2-methylene-cycloalkenones.
Joseph E; Ganem B; Eiseman JL; Creighton DJ
J Med Chem; 2005 Oct; 48(21):6549-52. PubMed ID: 16220971
[TBL] [Abstract][Full Text] [Related]
19. Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1.
Nelson CP; Kidd LC; Sauvageot J; Isaacs WB; De Marzo AM; Groopman JD; Nelson WG; Kensler TW
Cancer Res; 2001 Jan; 61(1):103-9. PubMed ID: 11196146
[TBL] [Abstract][Full Text] [Related]
20. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program.
Tew KD; Monks A; Barone L; Rosser D; Akerman G; Montali JA; Wheatley JB; Schmidt DE
Mol Pharmacol; 1996 Jul; 50(1):149-59. PubMed ID: 8700107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
